177 related articles for article (PubMed ID: 15036196)
1. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion.
Feldman ED; Wu PC; Beresneva T; Helsabeck C; Rodriguez M; Bartlett DL; Libutti SK; Pingpank JF; Alexander HR
J Gastrointest Surg; 2004 Feb; 8(2):200-7. PubMed ID: 15036196
[TBL] [Abstract][Full Text] [Related]
2. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
Bartlett DL; Libutti SK; Figg WD; Fraker DL; Alexander HR
Surgery; 2001 Feb; 129(2):176-87. PubMed ID: 11174711
[TBL] [Abstract][Full Text] [Related]
3. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.
Alexander HR; Bartlett DL; Libutti SK; Fraker DL; Moser T; Rosenberg SA
J Clin Oncol; 1998 Apr; 16(4):1479-89. PubMed ID: 9552055
[TBL] [Abstract][Full Text] [Related]
4. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy.
Alexander HR; Libutti SK; Bartlett DL; Pingpank JF; Kranda K; Helsabeck C; Beresnev T
Cancer; 2002 Aug; 95(4):730-6. PubMed ID: 12209715
[TBL] [Abstract][Full Text] [Related]
5. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies.
Libutti SK; Barlett DL; Fraker DL; Alexander HR
J Am Coll Surg; 2000 Nov; 191(5):519-30. PubMed ID: 11085732
[TBL] [Abstract][Full Text] [Related]
6. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms.
Alexander HR; Brown CK; Bartlett DL; Libutti SK; Figg WD; Raje S; Turner E
Clin Cancer Res; 1998 Oct; 4(10):2357-62. PubMed ID: 9796965
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic isolated liver perfusion for unresectable liver cancers: pilot study.
Lise M; Pilati P; Da Pian P; Mocellin S; Ori C; Casara D; Rossi CR; Darisi T; Corazzina S; Nitti D
J Chemother; 2004 Nov; 16 Suppl 5():37-9. PubMed ID: 15675475
[TBL] [Abstract][Full Text] [Related]
8. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver.
Alexander HR; Bartlett DL; Libutti SK
Oncologist; 2000; 5(5):416-24. PubMed ID: 11040278
[TBL] [Abstract][Full Text] [Related]
9. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives.
Rothbarth J; Tollenaar RA; Schellens JH; Nortier JW; Kool LJ; Kuppen PJ; Mulder GJ; van de Velde CJ
Eur J Cancer; 2004 Aug; 40(12):1812-24. PubMed ID: 15288282
[TBL] [Abstract][Full Text] [Related]
10. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center.
Alexander HR; Bartlett DL; Libutti SK; Pingpank JF; Fraker DL; Royal R; Steinberg SM; Helsabeck CB; Beresneva TH
Ann Surg Oncol; 2009 Jul; 16(7):1852-9. PubMed ID: 19434456
[TBL] [Abstract][Full Text] [Related]
11. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan.
Lindnér P; Fjälling M; Hafström L; Kierulff-Nielsen H; Mattsson J; Scherstén T; Rizell M; Naredi P
Eur J Surg Oncol; 1999 Apr; 25(2):179-85. PubMed ID: 10218462
[TBL] [Abstract][Full Text] [Related]
12. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia TNF alpha and melphalan: Swedish experience.
Hafström L; Naredi P
Recent Results Cancer Res; 1998; 147():120-6. PubMed ID: 9670274
[TBL] [Abstract][Full Text] [Related]
13. Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease.
Mocellin S; Pilati P; Da Pian P; Forlin M; Corazzina S; Rossi CR; Innocente F; Ori C; Casara D; Ujka F; Nitti D; Lise M
Ann Surg Oncol; 2007 Feb; 14(2):802-9. PubMed ID: 17103263
[TBL] [Abstract][Full Text] [Related]
14. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms.
Grover AC; Libutti SK; Pingpank JF; Helsabeck C; Beresnev T; Alexander HR
Surgery; 2004 Dec; 136(6):1176-82. PubMed ID: 15657573
[TBL] [Abstract][Full Text] [Related]
15. Isolated hepatic perfusion chemotherapy for unresectable malignant hepatic tumors.
Ku Y; Tominaga M; Iwasaki T; Fukumoto T; Kuroda Y
Int J Clin Oncol; 2002 Apr; 7(2):82-90. PubMed ID: 12018114
[TBL] [Abstract][Full Text] [Related]
16. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy.
Alexander HR; Libutti SK; Pingpank JF; Bartlett DL; Helsabeck C; Beresneva T
Ann Surg Oncol; 2005 Feb; 12(2):138-44. PubMed ID: 15827794
[TBL] [Abstract][Full Text] [Related]
17. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC
Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver Malignancies.
Burgmans MC; de Leede EM; Martini CH; Kapiteijn E; Vahrmeijer AL; van Erkel AR
Cardiovasc Intervent Radiol; 2016 Jun; 39(6):801-14. PubMed ID: 26718962
[TBL] [Abstract][Full Text] [Related]
19. Outcome analysis of a decade-long experience of isolated hepatic perfusion for unresectable liver metastases at a single institution.
Magge D; Choudry HA; Zeh HJ; Cunningham DE; Steel J; Holtzman MP; Jones HL; Pingpank JF; Bartlett DL; Zureikat AH
Ann Surg; 2014 May; 259(5):953-9. PubMed ID: 24169176
[TBL] [Abstract][Full Text] [Related]
20. Isolation perfusion of the liver.
Carroll NM; Alexander HR
Cancer J; 2002; 8(2):181-93. PubMed ID: 12004803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
